Moderna Announces Resignation of Dr. Elizabeth Nabel From Board of Directors
31 July 2020 - 6:27AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced the resignation of Elizabeth (Betsy)
Nabel, M.D., from Moderna’s Board of Directors effective today,
July 30. Dr. Nabel is President of Brigham and Women’s Hospital,
which is participating as one of 89 clinical trial sites in the
Phase 3 trial of mRNA-1273, Moderna’s vaccine candidate against
COVID-19.
“I would like to sincerely thank Betsy for her five years of
service on the Moderna Board. Her experience as a clinician, global
healthcare leader and researcher were instrumental in the progress
of Moderna’s clinical development,” said Noubar Afeyan, Ph.D.,
Co-Founder and Chairman of Moderna, and CEO of Flagship Pioneering.
“In the context of the start of the 30,000 participant Phase 3
trial for Moderna’s COVID-19 vaccine candidate, and Brigham and
Women’s Hospital’s final preparation as a site for enrolling up to
300-500 trial participants, we have accepted Betsy’s resignation
out of an abundance of caution to avoid any potential or even
apparent conflict of interest on her part or Moderna’s part.”
“It has been a privilege to work with Betsy over the last nine
years, first as a member of our Scientific Advisory Board, and over
the last five years as a member of our Board. I greatly appreciate
her contributions to the Moderna Board,” said Stéphane Bancel,
Moderna’s Chief Executive Officer. “Betsy’s extensive experience
and insights were critical to the advancement of Moderna’s mRNA
platform and helped us get to where we are today. I am grateful for
her tenure on the Board, for her counsel and her many
contributions.”
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that can have a therapeutic or
preventive benefit and have the potential to address a broad
spectrum of diseases. The company’s platform builds on continuous
advances in basic and applied mRNA science, delivery technology and
manufacturing, providing Moderna the capability to pursue in
parallel a robust pipeline of new development candidates. Moderna
is developing therapeutics and vaccines for infectious diseases,
immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca PLC
and Merck & Co., Inc., as well as the Defense Advanced Research
Projects Agency (DARPA), an agency of the U.S. Department of
Defense, and the Biomedical Advanced Research and Development
Authority (BARDA), a division of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) within the U.S.
Department of Health and Human Services (HHS). Moderna has been
named a top biopharmaceutical employer by Science for the past five
years. To learn more, visit www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730006042/en/
Moderna Contacts Media: Colleen Hussey Senior Manager,
Corporate Communications 203-470-5620
Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024